Hudson Bay Capital Management LP Has $15.24 Million Holdings in Galapagos NV (NASDAQ:GLPG)

Hudson Bay Capital Management LP increased its stake in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 8.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 554,300 shares of the biotechnology company's stock after acquiring an additional 44,300 shares during the period. Hudson Bay Capital Management LP owned 0.84% of Galapagos worth $15,243,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 974 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in Galapagos by 31.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock valued at $1,352,000 after buying an additional 11,777 shares during the last quarter. Gilead Sciences Inc. bought a new position in Galapagos in the 4th quarter worth $461,727,000. American Century Companies Inc. raised its holdings in Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after acquiring an additional 1,431 shares during the period. Finally, XTX Topco Ltd lifted its position in Galapagos by 137.8% during the 4th quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock worth $545,000 after acquiring an additional 11,492 shares during the last quarter. 32.46% of the stock is owned by institutional investors.

Galapagos Stock Performance

Shares of NASDAQ GLPG opened at $25.32 on Friday. Galapagos NV has a one year low of $22.36 and a one year high of $31.23. The business has a fifty day simple moving average of $25.41 and a 200 day simple moving average of $25.95.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The firm had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. Analysts predict that Galapagos NV will post -1.6 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on GLPG. Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and cut their price objective for the stock from $31.00 to $22.00 in a research report on Friday, February 14th. Barclays reiterated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, StockNews.com downgraded shares of Galapagos from a "hold" rating to a "sell" rating in a research note on Friday, April 25th. Five investment analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. According to MarketBeat, the stock has an average rating of "Reduce" and an average target price of $25.33.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.